Peninsula Alzheimer’s drug developer sheds third of value after part of trial halted

The nine-year-old company is pursuing a unique root cause for Alzheimer's — a common bacteria in the mouth — but liver problems in some patients caused the FDA to halt part of an important clinical trial.

Click to view original post